Now this is more the way I remember it...

Jason Butler - JMP Securities LLC

Okay, great. And then in the Type 2 trial, is it fair to say that you're not focusing on later stage patients at all? Or you're just broadening the population you enrolled in the previous trials to include earlier stage patients?

Peter Richardson - Chief Scientific Officer and Corporate Vice President

I think the thinking here is that actually with basal/bolus in effect a late stage Type 2 is very similar to a Type 1 and they're insulin dependent and that we will have a robust basal/bolus study in Type 1 patients. And we also have a very strong basal/bolus study with MedTone in Study 102 which I think is also historically important for us. So looking at ways that we can explore a broader Type 2 population, looking at patients who would perhaps be more normally treated with an oral therapy is a significant opportunity, and we want to look at the study designs that we can do for that. We have been looking at the possibilities of that in a Phase IIIB program. But I think to be able to use that as basis of registration is something that's a very interesting and exciting opportunity.

Alfred Mann - Founder, Chairman and Chief Executive Officer

Really I expected that we would have to do this basal/bolus trial in Type 2, as well. And the agency said that, that's not necessary that they are -- with the study with the new inhaler in Type 1 that would give them sufficient information to be able to apply basal/bolus therapy in both Type 1 and Type 2.

http://seekingalpha.com/article/268906-mannkind-s-ceo-discusses-q1-2011-results-earnings-call-transcript?find=type&all=false